Catalyst Wire Dossier Catalyst Wire Dossier

HLX79

human sialidase fusion protein · Shanghai Henlius Biotech
Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for HLX79, covering 2025-11-18 to 2025-11-18. Get the full timeline:

Most recent: Clinical Trial Update: A Study to Evaluate the Efficacy, Safety, and Tolerability of Human Sialidase Fusion Protein (HLX79) in Combination With Rituximab Injection Versus Placebo in Patients With Active Glomerulonephritis [Phase 2]

See pricing